Retatrutide Research: What Clinical Trials Actually Show About Weight Loss and Safety
Retatrutide has attracted enormous attention because of the weight-loss results reported in clinical trials. But how strong is the evidence, how does the medication work, and what do we still need to know about its safety?
The Short Answer
Retatrutide is an experimental medication being developed for obesity and related metabolic conditions.
Unlike peptides discussed mainly through animal studies, retatrutide has been evaluated in randomized human clinical trials.
A 2023 Phase 2 trial reported an average 24.2% weight reduction at 48 weeks in one treatment group. A Phase 3 trial published in September 2026 reported substantial weight reduction over 80 weeks.
Our takeaway: The weight-loss evidence is substantial, but side effects, longer-term safety, treatment durability, and regulatory approval remain important considerations.
What Is Retatrutide?
Retatrutide, also known by its research identifier LY3437943, is an investigational medication developed by Eli Lilly.
It belongs to a class of medicines that act on hormone receptors involved in appetite, blood sugar regulation, and energy metabolism.
Retatrutide is often described as a triple-receptor agonist because it targets three different receptors:
- GLP-1 receptors
- GIP receptors
- Glucagon receptors
This combination distinguishes it from medications that target one or two of these receptor systems.
It is being investigated as a potential treatment for obesity and related conditions, rather than as a general-purpose wellness supplement.
How Does Retatrutide Work?
Retatrutide activates three hormone-receptor pathways involved in metabolism.
GLP-1
GLP-1 receptor activation can influence appetite, feelings of fullness, and glucose regulation.
GIP
GIP is another incretin hormone involved in metabolic signaling and insulin regulation.
Glucagon
Glucagon receptors participate in glucose and energy metabolism. Researchers are investigating whether adding glucagon-receptor activity can produce additional benefits in combination with GLP-1 and GIP signaling.
The three pathways help explain the scientific rationale for retatrutide. However, biological mechanisms alone do not establish clinical safety or effectiveness.
What Did the Phase 2 Clinical Trial Show?
In 2023, researchers published a randomized, double-blind, placebo-controlled Phase 2 trial in the New England Journal of Medicine.
The study enrolled 338 adults with obesity or overweight plus a weight-related condition, without diabetes.
Participants were assigned to different retatrutide treatment groups or placebo and followed for 48 weeks.
The study reported different average outcomes across its treatment groups.
| Trial group | Average weight change at 48 weeks |
|---|---|
| Placebo | −2.1% |
| Retatrutide 1 mg | −8.7% |
| Retatrutide 4 mg, combined groups | −17.1% |
| Retatrutide 8 mg, combined groups | −22.8% |
| Retatrutide 12 mg | −24.2% |
These are trial outcomes, not recommended doses. They should not be used as instructions for self-administration.
The trial was funded by Eli Lilly, the developer of retatrutide.
What Do the Newer Phase 3 Results Show?
The evidence base expanded significantly in 2026 with results from the TRIUMPH-1 Phase 3 trial.
This randomized, double-blind trial evaluated retatrutide against placebo in adults with obesity without diabetes over 80 weeks.
Eli Lilly reported in May 2026 that participants in the 12-mg group experienced an average weight reduction of 28.3% at 80 weeks.
The Phase 3 research was subsequently published in the New England Journal of Medicine on September 29, 2026.
This is an important development because Phase 3 trials generally involve larger populations and are designed to provide more definitive evidence than early-stage studies.
However, the Phase 2 and Phase 3 percentages should not be compared as if they came from the same study. The trial populations, durations, and protocols differed.
How Is Retatrutide Different From Semaglutide and Tirzepatide?
Retatrutide is often discussed alongside two better-known weight-management medications: semaglutide and tirzepatide.
The main scientific distinction is the number of hormone-receptor pathways each activates.
| Medication | Receptor targets | Research context |
|---|---|---|
| Semaglutide | GLP-1 | Approved products have established clinical uses. |
| Tirzepatide | GIP and GLP-1 | Approved products have established clinical uses. |
| Retatrutide | GIP, GLP-1, and glucagon | Investigational triple agonist evaluated in Phase 2 and Phase 3 trials. |
More receptor targets do not automatically mean a medication is safer or better for every patient.
Comparing weight-loss percentages from separate trials can also be misleading. A reliable direct comparison requires appropriately designed head-to-head studies.
What Are the Side Effects and Safety Concerns?
Strong weight-loss results do not eliminate the importance of safety research.
In the 2023 Phase 2 trial, the most common adverse events were gastrointestinal.
Reported problems included symptoms such as nausea, vomiting, and diarrhea.
Gastrointestinal adverse events were generally more frequent with greater drug exposure and were mostly mild to moderate in that study.
Researchers also observed increases in heart rate that varied with treatment group and changed over time.
What about long-term safety?
Longer Phase 3 trials provide additional safety information, but they do not answer every question about years of treatment or rare adverse events.
Important questions include:
- How well patients tolerate treatment over extended periods.
- Whether rare or serious adverse events emerge in larger populations.
- What happens to weight after treatment stops.
- How treatment affects nutrition, lean mass, and quality of life.
- Which patients are most likely to benefit or experience harm.
Is Retatrutide FDA-Approved?
As of this October 2026 article update, retatrutide remains described as investigational in the clinical development sources referenced here.
Successful clinical trials and published results are not the same as regulatory approval.
Approval requires a separate regulatory review of effectiveness, safety, manufacturing, and other evidence.
Readers should verify the latest FDA status before relying on any statement about availability.
What Do We Still Need to Learn?
Retatrutide’s clinical results are promising, but there are still meaningful research questions.
Will weight loss be maintained?
Weight management is a long-term challenge. Researchers need to understand what happens after treatment is discontinued and which maintenance strategies work.
What happens to muscle mass?
Large changes in body weight can involve changes in fat mass and lean mass.
Future analyses should help clarify body composition outcomes and how best to preserve physical function.
Who benefits most?
Average results do not mean everyone responds in the same way.
Age, medical conditions, other medications, and individual biology may influence outcomes.
How does it compare directly with existing treatments?
Direct comparative trials can provide better answers than comparing percentages from unrelated studies.
Frequently Asked Questions
How much weight did participants lose in retatrutide studies?
In the 2023 Phase 2 trial, one treatment group had an average 24.2% weight reduction at 48 weeks. In 2026, the TRIUMPH-1 Phase 3 results reported an average 28.3% reduction in one group at 80 weeks. Individual outcomes vary.
Is retatrutide a GLP-1 medication?
It activates GLP-1 receptors, but also targets GIP and glucagon receptors. That makes it a triple-receptor agonist.
Is retatrutide the same as tirzepatide?
No. Tirzepatide targets GIP and GLP-1 receptors. Retatrutide also targets glucagon receptors.
Does retatrutide work for everyone?
No treatment produces identical outcomes for every person. Clinical trial averages describe groups, not guaranteed individual results.
What are the common side effects?
Gastrointestinal symptoms such as nausea, vomiting, and diarrhea were common in clinical research. Changes in heart rate were also observed.
Can retatrutide be purchased as a research peptide?
Products may be advertised online, but that does not establish their authenticity, quality, safety, or legal suitability for human use. The investigational medication studied in clinical trials should not be equated with unapproved products sold online.
Is retatrutide better than semaglutide?
Retatrutide has shown substantial weight loss in its trials, but comparing results across different studies cannot reliably determine which treatment is better for an individual patient.
Our Final Take
Retatrutide represents an important area of obesity research because its results come from randomized human clinical trials rather than relying primarily on animal studies or testimonials.
The published findings demonstrate substantial average weight reduction in the populations studied.
But those results should be discussed alongside side effects, uncertainty about long-term outcomes, and regulatory status.
The goal of What I Tried is not to dismiss promising research or turn it into a sales pitch.
It’s to help readers understand what the evidence actually supports.
Sources and Further Reading
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 2023. Read the study .
- Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine, September 2026. Read the Phase 3 study .
- ClinicalTrials.gov. TRIUMPH-1: A Study of Retatrutide in Participants Who Have Obesity or Overweight. NCT05929066. View the trial record .
- Eli Lilly. Retatrutide Delivered Powerful Weight Loss in Pivotal Phase 3 Obesity Trial. May 21, 2026. Read the company results announcement .
- U.S. Food and Drug Administration. Drugs@FDA. Official approval database .
Editorial note: This article distinguishes published clinical findings from company announcements, and trial averages from individual expectations. It has not been independently medically reviewed. Research and regulatory status may change after publication.